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Three data mining algorithms (J48, LADtree, NaiveBayes) and a non-data mining based algorithm were used for classiﬁcation.
The selected reports were reviewed and annotated by 2 radiation oncologists according to the 7th edition TNM staging system.
The rates of coincidence between the algorithms and the manual detection were assessed by the Cochran’s Q test.
Results. The non-data mining based algorithm had the highest percentage of correctly classiﬁed cases running both the test
dataset and the validation set (96% and 99%, respectively). There were signiﬁcant differences between the results of the various
algorithms used (P=0.001). The reasons for the errors in the classiﬁcation by the algorithms were mainly due to the lack of
recognition of multifocal status and inﬂammatory disease.
Conclusions. This system based on artiﬁcial intelligence automatically enables the classiﬁcation of tumor size in breast cancer.
This tool would help saving time in the data collection, preventing errors, and improving tumor classiﬁcation as well as the
quality of the therapeutic decision.
http://dx.doi.org/10.1016/j.rpor.2013.03.644
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Introduction. Radiation therapy is an integral part in the combined treatment of breast cancer. The beneﬁt is well established in
terms of both local control and survival endpoints. Helical Tomotherapy has been proposed as an alternative to standard 3D
conformal radiotherapy.
Purpose. To evaluate dosimetric characteristics of Helical Tomotherapy for breast cancer radiotherapy.
Methods and materials. Nine patients with histologically proven breast cancer affecting internal mammary chain (clinically and/or
histologically conﬁrmed) stage IIIC, were included in this study. CT simulation scans were used to contour the planning target
volumes (PTV) including the chest wall/breast, supraclavicular, axillary, and internal mammary lymph nodes. Dose prescription
was 50/50.4, in 25/28 fractions of 2/1.8Gy, to the PTV and treatment planning objectives were to cover at least 95% of the planning
target volume with the 95% isodose. Beamlet entrance and/or exit throughout critical structures was blocked to protect the lungs,
heart, and contralateral breast.
Results. Median homogeneity index (maximum dose/prescribed dose) was 1.23 (range 1.05–1.48). Median coverage index (min-
imum dose/prescribed dose) was 0.72 (range 0.54–0.9) Median V30, V20 and V5 for ipsilateral lung was 16.72% (range 0–26.5%),
30.8% (range 10.62–40%) and 97.6% (range 64.46–100%) respectively. Median V30, V20 and V5 for contralateral lung was 0% (range
0–0.48%), 0.095% (range 0–2.58%) and 49% (range 5.84–92.38%) respectively. Median V30, V20 and V5 for heart was 1.112% (range
0–4.6%), 4% (range 0.025–15.44%) and 96.52% (range 27.3–100%) respectively. Median V20, V10 and V5 for contralateral breast was
0% (range 0–0.37%), 1.25% (range 0.1–11.82%) and 28% (range 15.53–49.4%) respectively.
Conclusion. HT offers acceptable dose distribution. This technique achieves high homogeneity and conformality, and reduces the
hot-spots in organs at risk although increasing the low dose areas However clinical advantage of using HT in breast cancer is
unknown. Further studies of long monitoring period are required.
http://dx.doi.org/10.1016/j.rpor.2013.03.645
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Introduction. Postmastectomy radiotherapy has an important role in terms of survival and quality of life in breast cancer. It has
demonstrated superior locoregional control. Women who required RTPM represent a great reconstructive challenge. Optimal
management of women who have undergone RTPM and reconstruction for breast cancer requires a multimodality approach.
Breast reconstruction can be carried out immediate or delayed. The adequate decision is based on optimize outcomes and
minimize complications. Despite patients who need radiation are more suitable for delayed reconstruction, in this study we
analyze a series of patients treated with RT in our center who undergone immediate reconstruction.
Method. We studied twenty patients treated with postmastectomy radiotherapy who underwent immediate reconstruction and
twenty patients without reconstruction from 2007 to 2012. The prescribed dose was 50Gy in 25 fractions and those who received
also boost was 16Gy in 8 fr. The implant used was tissue expander and one was directly a prosthesis. The staging most frequently
was III. The type of procedure was in all cases modiﬁed radical mastectomy and one simple mastectomy.
Results. The acute toxicity (1 month) was dermatitis Grade I and no toxicity at 6 months in the immediate reconstruction group
and dermatitis G1 and G2 in the PMRT without reconstruction group, based in the toxicity criteria of the Radiation Oncology
Therapy Group. There was nor infection neither deﬂation. In one of them was developed capsular contractured that required
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the replacement of the tissue expander with a prosthesis after ﬁnishing radiotherapy (5%). Tissue expansion was performed
before the treatment in all cases. Pulmonary irradiation was inferior in reconstruction group based in V20 lung doses. Aesthetic
satisfaction is similar in both but psycological impact and quality of life was better in the immediate reconstruction group.
Conclusion. Immediate reconstruction has shown to be safe and has advantages compared differed reconstruction in patients
with postmastectomy radiotherapy, it has similar complication rates and general satisfaction with controls, but increased lung
irradiation sparing, esthetic satisfaction and quality of life.
http://dx.doi.org/10.1016/j.rpor.2013.03.646
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Introduction. Neoadjuvant chemotherapy (nCT) in resectable early stage breast cancer is controversial. We treated 57 women with
nCT, surgery and radiotherapy. Purpose Results evaluation and local recurrence prognostic factors analysis.
Methods. Mean clinical tumor size by physical examination was 3.97 cm (SD 1.28), 2.87 cm by mammography (SD 1.07) and 3.24 cm
by MRI. Mean clinical axillary lymph nodes size was 2.44 cm (SD 1.24). Axillary US was performed in 54.2% ﬁnding 44.1% cN0,
35.6% cN1, 15.3% cN2 and 1.7% cN3. MRI was performed in 63.1%. The most prevalent histology was IDC. Histologic G1 was found
in 18.6%, 37.2% G2 and 40.7% G3. There were 50.8% Luminal A, 4.9% Luminal B and 26.3% triple-negative. The most common CT
scheme was Taxanes (86.2%). Hematologic toxicity (G2-3): 6 cases. Non-hematologic toxicity: 3 cases.
Results. Mean clinical–radiological responses were 76.8% and 70.4%. CBS was performed in 91.2%, mastectomy in 8.8%. Mean
pathological tumor size was 1.16 cm (SD 0.28). Partial and complete pathological responses were 74.5% and 25.5%. Adjuvant RT:
5000 cGy WBI, 200 cGy/fr (84.7%); 4005 cGy WBI, 267 cGy/fr (13.6%). Lymph node irradiation was performed in 50.8%. 1600 cGy
BOOST was delivered in 55 cases. Concomitant CT-RT treatment: 36 cases, Herceptin (29,3%) and Tamoxifen (15.5%). Acute
radiodermitis: 60.3% G1, 32.8% G2 and 3.4% G3. Mean follow-up was 16.4 months (r:6–57). 97.5% patients are disease-free, LRFS
87%.
Conclusions. It seems that nCT increases BCS percentage. Further studies, with patient selection based in standard pretreatment
criteria and longer follow-up, are necessary to obtain deﬁnitive conclusions.
http://dx.doi.org/10.1016/j.rpor.2013.03.647
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Background. Triple-negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor,
progesterone receptor or Her2/neu. Standard treatment is surgery +/− adjuvant chemotherapy and radiotherapy. TNBC tends to
be more aggressive than other types of breast cancer. Studies have shown that TNBC is more likely to spread beyond the breast
and more likely to recur after treatment. The purpose of this study is to assess the outcome of BC patients treated with surgery
+/− chemotherapy and adjuvant radiation therapy according the molecular subtype. We present preliminary data, the study is
ongoing.
Methods and materials. One hundred and sixteen female patients diagnosed with BC between 2004 and 2013 were analyzed
retrospectively. The TNM classiﬁcation was as follows: 6 stage 0 (TisN0M0), 61 stage I, 37 stage II, and 12 stage III. The vast
majority of patients (88%) underwent conservative surgery. Fifty-three patients received adjuvant chemotherapy. All patients
received postoperative radiation therapy (dose range, 40–50Gy). Nine (7.8%) out of the 116 patients were TNBC. Potential risk
factors were analyzed in univariate analysis.
Results. The median age at diagnosis was 55 years old (range, 30–83) and the median follow up 42 months (range, 1–72). Six
relapses occurred, all were TNBC (2 distant and 4 both local and distant). Univariate analysis showed two signiﬁcant predictors
for recurrence: TNBC (OR: 17.33; p=0.012) and mastectomy (OR: 9.00; p=0.012).
Conclusions. TNBC is associated with a higher risk of relapse compared with luminal subtypes. Prospective randomized studies
are needed to investigate the best locoregional treatment approach for patients with this molecular subtype who potentially
may beneﬁt from more aggressive local treatment. The development of novel therapies should target this high-risk group.
http://dx.doi.org/10.1016/j.rpor.2013.03.648
